来自于英国的研究人员 Peter Clark 教授及其同事对967名妊娠妇女进行了全面的莱顿因子 V 的筛查,从而使2.5%的母亲并发症和0.5%的新生儿死亡得以预防,并降低了50%的并发症发病率。在对筛查的真实费用加以评估后,研究人员得出的最终结论是无任何潜在的费效价值;因为新生儿死亡并不能被简单地归因于妊娠综合征,反而有可能贯穿其一生,持续77年。假设新生儿的未来生活有赖于整个筛查过程, Prof Peter Clark, a researcher from the United Kingdom, and her colleagues screened 967 pregnant women for a comprehensive screening of the Leiden Factor V, which resulted in a 2.5% reduction in maternal complications and 0.5% neonatal death and reduced 50% complication rate. After assessing the true cost of screening, the researchers concluded that there was no potentially cost-effective value; since neonatal deaths can not simply be attributed to gestational syndrome, they are likely to run through their lives, For 77 years. Assuming that the newborn’s future life depends on the entire screening process,